Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence AAHLPAEFTPAVHASLDKFLASVSTVL
Primary information
sequence IDSeq_49
Peptide sequenceAAHLPAEFTPAVHASLDKFLASVSTVL
CancerPDF_ID CancerPDF_ID10646, CancerPDF_ID11087, CancerPDF_ID11100,
PMID21805675,26482227,26482227
Protein NameHemoglobin subunit alpha,HBA_HUMAN,HBA_HUMAN
UniprotKB Entry NameHBA_HUMAN,HBA_HUMAN,HBA_HUMAN
FluidUrine,Urine,Urine
M/Z2792.4821,2790.7,2790.7
ChargeNA,NA,NA
Mass (in Da)NA,NA,NA
fdrNA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF
Peptide Identification techniqueMALDI-TOF-MS,LC-ESI-MS/MS,LC-ESI-MS/MS
Quantification TechniqueNA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDR1,FDR less than 5 %,FDR less than 5 %
CancerPDF_ID CancerPDF_ID10646, CancerPDF_ID11087, CancerPDF_ID11100,
p-ValueNA,NA,less than 0.05
SoftwareNA,MASCOT,MASCOT
Length27,NA,NA
Cancer TypeMuscle-invasive bladder cancer,Clear cell renal carcinoma,Clear cell renal carcinoma
DatabaseSwissProt Database,SwissProt Database,SwissProt Database
ModificationNA,NA,NA
Number of Patients751 bladder cancer and 127 control,"117 clear cell RCC patients (ccRCC) (72 men, 45 women)","117 clear cell RCC patients (ccRCC) (72 men, 45 women)"
RegulationDifferentially expressed between cancer vs normal samples,"Differentially expression in control vs ccRCC cancer, Primary Tumor or grade",Upregulated in pT1b compared to pT1a patients
ValidationMann-Whitney tests and areas under receiver-operator characteristic,external cross validation not done,external cross validation not done
SensitivityNA,NA,NA
SpecificityNA,NA,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB144183